

## INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

<b>Adenosine triphosphate (ATP),</b>	
content in <i>M. leprae</i> . DHOPLÉ, A. M. and HANKS, J. H. ....(O)	57
<b>Africa,</b>	
leprosy control in The Gambia. Meesters, H. J. R. ....(A)	140
<b>American Leprosy Missions (ALM),</b>	
receives 1981 Damien-Dutton Award ....(N)	347
Workshop on Training ....(N)	265
25th International Seminar on Leprosy ....(N)	265
75th anniversary ....(N)	356
<b>Amyloidosis,</b>	
in leprosy. Gupta, J. C. and Pandya, P. K. ....(A)	129
renal, histological and biochemical assessment of severity of. Bhuyan, U. N. ....(A)	486
SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders. Lack of association with amyloid disease. Scheinberg, M. A. and Benson, M. D. ....(A)	474
serum electrophoretic pattern in, complicating tuberculosis. Patra, S. B., <i>et al.</i> ....(A)	488
<b>Andrade, Roberto Nuñez,</b>	
obituary. Saúl, A. ....(Ob)	83
<b>Antibodies,</b>	
against <i>M. leprae</i> antigen 7 from birth to 18 months of age: an indicator of intra- uterine infection in leprosy. Mathias, C., <i>et al.</i> ....(A)	133
demonstration of, reacting with different determinants on <i>M. leprae</i> antigen 7. Harboe, M., <i>et al.</i> ....(A)	147
enzyme-linked immunosorbent assay (ELISA): a study of . . . to <i>M. tuberculosis</i> . Grange, J. M., <i>et al.</i> ....(A)	144
mycobacterial, response to nine, for an . . . common to tuberculosis and lepromatous leprosy. Kaplan, M. H. and Chase, M. W. ....(A)	275
monoclonal, antigenic relationships between <i>M. leprae</i> and other mycobacteria de- fined by absorbed leprosy sera and. Gillis, T. P. and Buchanan, T. M. ....(A)	504
responses <i>in vitro</i> by BCG, <i>M. leprae</i> , and <i>Corynebacterium parvum</i> , phagosome/ lysosome fusion. Brown, C. A., <i>et al.</i> ....(A)	275
use of the ELISA to screen for anti-thymocyte and anti- $\beta_2$ -microglobulin, in leprosy and SLE. Bahr, G. M., <i>et al.</i> ....(A)	273
<b>Antigen(s),</b>	
Australian, incidence of, in leprosy. Lenka, M. R., <i>et al.</i> ....(A)	271
—, subtypes of, in leprosy in São Paulo. Ottati, S. and Candeias, J. A. N. ....(A)	272
cutaneous responses to, and irritants in patients of leprosy. Kumar, B., <i>et al.</i> ....(A)	132
Dharmendra, assessment of. Sinha, S., <i>et al.</i> ....(A)	276
—, —, diluted. Kumar, B., <i>et al.</i> ....(A)	132
histocompatibility, in leprosy. Park, E. S., <i>et al.</i> ....(A)	376
HLA, distribution of, in Ticuna Indians of Brazil. Lawrence, D. N., <i>et al.</i> ....(A)	132
<i>M. leprae</i> . . . 7. HARBOE, M., <i>et al.</i> ....(O)	147
—, comparison of 22 species of mycobacteria by immunodiffusion against an absorbed leprosy serum. GILLIS, T. P., <i>et al.</i> ....(O)	287
— specific, obtained by lithium acetate extraction procedure. BUCHANAN, T. M., <i>et al.</i> ....(C)	88
—, —. HARBOE, M. and CLOSS, O. ....(O)	85
mycobacterial, <i>in vitro</i> stimulation of human lymphocytes with. WRIGHT, E. P. and RANGARAJAN, R. ....(C)	455
reactivity to, of various mycobacterial species. Vandiviere, H. M., <i>et al.</i> ....(A)	284
<b>Argentina,</b>	
antileprosy battle in Sante Fe. Lehrer, A. B. and Bonnucci, N. E. ....(A)	483
XXV Conference of the International Union against tuberculosis. ....(N)	97

Grupos de Investigación de la Enfermedad de Hansen (GRIHAN). . . . .	(N)	97
La Sociedad Argentina de Leprología conference. . . . .	(N)	261
<b>Armadillo (nine-banded) (<i>Dasyus novemcinctus</i>),</b>		
— grown <i>M. leprae</i> to study antigenic detail. HARBOE, M. and CLOSS, O. . . . .	(C)	85
ATP content harvested from, using firefly bioluminescence method. DHOPLE, M. and HANKS, J. H. . . . .	(O)	57
case of natural splenic mycobacteriosis in, with histopathologic and tinctorial characteristics similar to leprosy. Resoagli, E. H., <i>et al.</i> . . . . .	(A)	139
feral, mycobacteria obtained from, failure to detect <i>o</i> -diphenoloxidase in. Prabhakaran, K., <i>et al.</i> . . . . .	(A)	281
in captivity: prevention of losses due to parasitic diseases. KAZDA, J. M. . . . .	(C)	345
infected, lipid constituents of <i>M. leprae</i> isolated from. Asselineau, C., <i>et al.</i> . . . . .	(A)	372
liver of, occurrence of superoxide dismutase in <i>M. leprae</i> grown on. Kusunose, E., <i>et al.</i> . . . . .	(A)	278
mycobacterial lipids in biopsies of. YOUNG, D. B. . . . .	(O)	199
proteins of, that contaminate <i>M. leprae</i> during its purification. Quesada-Pascual, F., <i>et al.</i> . . . . .	(A)	506
<b>Aspiration cytology,</b>		
of lymph nodes in leprosy. Gupta, S. K., <i>et al.</i> . . . . .	(A)	9
<b>Australia,</b>		
— wide leprosy seminar. . . . .	(N)	460
<i>Leprosy in Tropical Australia.</i> Hargrave, J. C. and Jones, E. R. . . . .	(B)	115
<b>Bacterial Index (BI),</b>		
choice of skin slit smears for study of . . . and MI. Kaur, S., <i>et al.</i> . . . . .	(A)	129
<b>BCG,</b>		
— vaccination with, borderline tuberculoid leprosy following. STONER, G. L., <i>et al.</i> . . . . .	(O)	16
—, —, trial of, in South India for tuberculosis prevention. . . . .	(A)	145
—, —, and lepromin-A administered contemporaneously seen in a separated positive association. Tarabini-Castellani, G., <i>et al.</i> . . . . .	(A)	480
effect of, on protective efficacy of two distinct forms of cell-mediated response to. Rook, G. A. W., <i>et al.</i> . . . . .	(A)	276
efficacy, of protective, how environmental mycobacteria may predetermine. Stanford, J. L., <i>et al.</i> . . . . .	(A)	277
granulomatous response of leprosy patients to killed . . . and lepromin. Hans, S. H., <i>et al.</i> . . . . .	(A)	476
inducing immunity to <i>M. leprae</i> in mice. Ganguly, N. K., <i>et al.</i> . . . . .	(A)	280
inoculation of lepromin-A . . . in cases that are negative to three successive lepromin tests. Tarabini-Castellani, C., <i>et al.</i> . . . . .	(A)	480
Mitsuda test, in healthy vaccinated cases who were not vaccinated with antituberculous BCG. Tarabini-Castellani, C., <i>et al.</i> . . . . .	(A)	479
—, with lepromin-A, in cases pre-treated for 6 months with a mixture of . . . and lepromin-A. Tarabini-Castellani, G., <i>et al.</i> . . . . .	(A)	479
— -primed mouse spleens, cultures of. <i>Corynebacterium parvum</i> or <i>M. leprae</i> added to. Brown, C. A., <i>et al.</i> . . . . .	(A)	273
treatment of lepromatous leprosy with. Villa, S. Z., <i>et al.</i> . . . . .	(A)	480
WHO experts recommend continued use of, against tuberculosis. . . . .	(N)	464
<b>Belgium,</b>		
Damien Foundation publishes Atlas of Leprosy Distribution. . . . .	(N)	97
— revises Atlas of Leprosy Distribution. . . . .	(N)	460
<b>Biopsy,</b>		
fine needle aspiration. GUPTA, S. K., <i>et al.</i> . . . . .	(O)	9
from leprosy patients, detection of mycobacterial lipids in. YOUNG, D. B. . . . .	(O)	198
<b>Blood,</b>		
low serotonin uptake by platelets in leprosy. SZABADOS, L., <i>et al.</i> . . . . .	(O)	42
test, evaluation of, for potential to indicate leprosy infection prior to appearance of clinical symptoms. REICH, C. V., <i>et al.</i> . . . . .	(O)	21
<b>Bone(s),</b>		
alterations in, in Hansen's disease. Cardama, J. E., <i>et al.</i> . . . . .	(A)	484

<i>Artropatia Hanseniana</i> . Moleris Ferrandis, R. ....(A)	472
tarsal . . . disintegration in Hansen's disease patients. Gabrielli, M., <i>et al.</i> ....(A)	142
<b>Borderline,</b>	
— leprosy, histological course of reactions in, and their outcome. RIDLEY, D. S. and RADIA, K. B. ....(O)	383
— tuberculoid leprosy following BCG vaccination. STONER, G. L., <i>et al.</i> ....(O)	16
<b>Brazil,</b>	
distribution of HLA antigens in Ticuna Indians. Lawrence, D. N., <i>et al.</i> ....(A)	132
situation of endemic Hansen's disease in the state of São Paulo. Belda, W. and Lombardi, C. ....(A)	482
<b>Browne, Stanley G.,</b>	
<i>Mister Leprosy</i> , biography of. Thompson, P. ....(B)	266
personal. ....(N)	357
<b>Canada,</b>	
Secours aux Lepreux (SLC) becomes member of ILEP. ....(N)	349
<b>Caribbean, The,</b>	
surveillance of communicable diseases in, 1979. Hansen's disease. Nalli, G. A. and Pearson, D. A. ....(A)	282
<b>Cat leprosy,</b>	
observations of, in New Zealand. Thompson, E. J., <i>et al.</i> ....(A)	284
<b>Cells,</b>	
mononuclear, effector function of, from leprosy patients. Humphres, R. C., <i>et al.</i> ....(A)	514
spindle-shaped leproma, arising from perineurium, a link with Wade's histoid leprosy. Gaulier, A. ....(A)	476
studies on T cell subsets and functions in leprosy. Bach, M.-A., <i>et al.</i> ....(A)	475
suppressor, decreased, activity in disseminated granulomatous infections. Artz, R. P., <i>et al.</i> ....(A)	465
— T, evidence for <i>in situ</i> activation of, in lepromatous leprosy. Mehra, V., <i>et al.</i> ....(A)	515
<b>Chemotherapy,</b>	
antileprotic action of an extract from "anantamul." Gupta, P. N. ....(A)	469
antimycobacterial activity of 2-acetylpyridine thiosemicarbazones in relation to their antileprosy activity. MORRISON, N. E. and COLLINS, F. M. ....(O)	180
clinical trials with Ciba 1906 in lepromatous leprosy. Anand, L. C., <i>et al.</i> ....(A)	360
drug interaction, influence of rifampin and clofazimine on the urinary excretion of DDS. Balakrishnan, S. and Seshadri, P. S. ....(A)	268
effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth. David, H. L., <i>et al.</i> ....(A)	122
evaluation of multiple drug regimens in leprosy. Ramu, G., <i>et al.</i> ....(A)	363
combined, against <i>M. leprae</i> in the mouse. Pattyn, S. R. and Van Loo, G. ....(A)	125
multi-drug, a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH, and thiacetazone in lepromatous cases. Kundu, S. K., <i>et al.</i> ....(A)	362
—, treatment for reactions in leprosy. Abdul Razack, E. M. ....(A)	269
of leprosy, present status and future prospects of, based on experience with treating tuberculosis. ACOCELLA, G. ....(E)	331
study on drug interactions. Venkatesan, K. ....(A)	127
treatment of lepromatous leprosy with a combination of rifampin and isoprodian. Colin, M. and de Montaigne, E. ....(A)	269
<b>Children,</b>	
leprosy in. Lal, S. ....(A)	268
—, psychodynamic side of. Children's Apperception Test (CAT) study. Chauhan, N. S. and Dhar, U. ....(A)	484
—, study in an urban slum. Jayam, S., <i>et al.</i> ....(A)	282
Miyako Islands, FLA-ABS and lepromin tests in, immuno-epidemiological studies on subclinical infection with <i>M. leprae</i> . Abe, M., <i>et al.</i> ....(A)	503
<b>China, People's Republic of,</b>	
decline of leprosy in. SKINSNES, O. ....(C)	341

- general condition of work on prevention and treatment of leprosy in. MA HAIDE and YE GAN-YUN. ....(E) 218
- ILA President, Dr. Michel F. Lechat, visits China. ....(N) 268
- Skinsnes, Dr. O. lectures in. ....(N) 106
- WHO Technical Visiting Group visit. ....(N) 353
- Cholinesterase,**
- serum, its genetic variants in leprosy patients. Terencio de las Aguas, J., *et al.* ....(A) 142
- Circulating immune complexes (CIC),**
- detected by Clq solid phase assay in leprosy. NUTI, M., *et al.* ....(O) 27
- in cervical cancer: simple method for detection and characterization. Seth, P. and Srinivas, R. V. ....(A) 488
- Clinical symptoms of leprosy,**
- new blood test to indicate leprosy infection prior to appearance of. REICH, C. V., *et al.* ....(O) 21
- Clofazimine,**
- and dapsone, a combination therapy in ENL syndrome. Dutta, R. K. ....(A) 122
- after 16 years—the best antileprosy drug? Jacobson, R. R. ....(A) 510
- analogs, activity of four against *M. leprae*. Levy, L. ....(A) 362
- clinical evaluation of, in vitiligo. Shak, K. C. ....(A) 488
- gastro-intestinal side effects of. Lal, S., *et al.* ....(A) 362
- in lepra reactions. Imkamp, F. M. J. H. ....(A) 470
- in treatment of annular lupus erythematosus. Crovato, F. and Levi, L. ....(A) 377
- in treatment of lepromatous leprosy in the United Kingdom. 12-year review of 31 cases. BROWNE, S. G., *et al.* ....(O) 167
- intra-neural ceroid-like pigment following treatment of lepromatous leprosy with. McDougall, A. C. and Jones, R. L. ....(A) 362
- radiological abnormalities of the ileum associated with the use of, in the treatment of skin ulceration due to *M. ulcerans*. de Bergeyck, E., *et al.* ....(A) 122
- Clq solid phase assay,**
- to detect circulating immune complexes in leprosy. NUTI, M., *et al.* ....(O) 21
- Contacts, of leprosy patients,**
- a study of. Govila, A. K. and Kushwah, S. S. ....(A) 140
- lepromin reaction in child contacts and non-contacts in Chengalpattu District, Tamil Nadu. Ramu, G., *et al.* ....(A) 141
- results of an enzyme-linked immunosorbent assay using arabinomannan from *M. smegmatis*. Miller, R. A. and Buchanan, T. M. ....(A) 506
- Corynebacteria,**
- leprosy-derived, primary structure of the wall peptidoglycan of. Janczura, E., *et al.* ..(A) 372
- Cyclophosphamide,**
- effect of, on course of *M. lepraemurium* infection. Alexander, J. ....(A) 279
- Cytology,**
- aspiration, of lymph nodes in leprosy. GUPTA, S. K., *et al.* ....(O) 9
- Damien Dutton Award,**
- awarded to American Leprosy Missions. ....(N) 347
- to Mr. Robert Watelet. ....(N) 260
- list of previous recipients. ....(N) 261
- Damien, Father**
- Damien, the Leper Priest.* Neimark, A. E. ....(B) 117
- Dapsone,**
- action of. SEYDEL, J. K. ....(C) 90
- and rifampin, changes in neutrophil motility. Anderson, R. and Gatner, E. M. S. ....(A) 360
- assaying, in mouse diets. Ellard, G. ....(A) 269
- assessment of self-administration of, in urine. Balakrishnan, S. and Christian, M. ....(A) 122
- clofazimine and, a combination therapy in ENL syndrome. Dutta, R. K. ....(A) 122
- effect of, on blood pyruvate and lactate levels in leprosy patients. Bharadwaj, V. P., *et al.* ....(A) 128

—, on nude mice experimentally infected with <i>M. leprae</i> . Bharadwaj, V. P., <i>et al.</i> . . .(A)	508
erythema multiforme bullosum due to. Dutta, R. K. . . . .(A)	123
fatal reaction to, during treatment of leprosy. Frey, H. M., <i>et al.</i> . . . .(A)	469
fluorimetric screening of, in urine for drug trials. Balakrishnan, S. . . . .(A)	121
haemolysis in leprosy. Menezes, S., <i>et al.</i> . . . . .(A)	270
-induced hypohaptoglobinemia in lepromatous leprosy patients. SRITHARAN, V., <i>et al.</i> (O)	307
in treatment of leprosy patients in Papua New Guinea. Ree, G. H. and Taylor, V. E. (A)	126
<i>in vitro</i> and <i>in vivo</i> effects of, on neutrophil and lymphocyte functions. Anderson, R., <i>et al.</i> . . . . .(A)	360
optic atrophy and motor neuropathy induced by. Homeida, M., <i>et al.</i> . . . . .(A)	361
patient compliance with the administration of. HUIKESHOVEN, H. . . . .(E)	228
profile of urinary. . . /creatinine ratios after oral dosage with. Ellard, G. A. . . . .(A)	123
reply to Dr. van der Meulen and Dr. Mock's Letter to the Editor. NAAFS, B. . . . .(C)	459
reversal reaction, management of, 100 mg daily, the cornerstone. VAN DER MEULEN, J. and Mock, B. . . . .(C)	457
self-administration of, by leprosy patients in Ethiopia. Ellard, G. A., <i>et al.</i> . . . . .(A)	469
still first choice in leprosy. Modderman, E. S. M. . . . . .(A)	271
study of, in leprosy control. Ko, Y. H. . . . . .(A)	362
toxic psychosis after accidental ingestion of. Krishna Murthy, K. and Raja Babu, K. K. . . . . .(A)	124
trials for chemoprophylaxis of leprosy by, fundamental studies on an artificial DDS- rice. Gidoh, M., <i>et al.</i> . . . . .(A)	269
with rifampin 1200 mg once monthly and daily Lamprene <sup>®</sup> , in treatment of refractory patients with lepromatous leprosy. PAUL, S. and ROSE, E. T. . . . .(C)	342
<b>Dapsone resistance,</b>	
in a population of Bamako (Mali). Baquillon, G., <i>et al.</i> . . . . .(A)	268
in Cebu, Philippines. GUINTO, R. S., <i>et al.</i> . . . . .(O)	427
in lepromatous leprosy, clofazimine in the treatment of. BROWNE, S. G., <i>et al.</i> . . . . .(O)	167
problem of, in leprosy. PEARSON, J. M. H. . . . . .(O)	417
—, the THELEP approach. . . . . .(O)	421
in pregnancy, in leprosy. Duncan, M. E., <i>et al.</i> . . . . .(A)	471
<b>Denmark,</b>	
joint WHO-ILA meeting. Hastings, R. C. . . . . .(N)	460
<b>Disability(ies),</b>	
appreciating the consequences of disease: the <i>International Classification of Impairments, Disabilities, and Handicaps</i> . Wood, P. H. N. . . . . .(A)	142
of Hansen's disease. Goncalves, A. . . . . .(A)	485
<i>The Economics of Disability: International Perspectives</i> . Rehabilitation International in cooperation with the United Nations. . . . . .(B)	358
<b>Drug metabolism,</b>	
in leprosy. Sharma, S. C., <i>et al.</i> . . . . .(A)	126
<b>Dutton, Brother Joseph,</b>	
<i>Brother Joseph Dutton, 1843–1931, A Saint for Vermont</i> . Halpern, R. . . . . .(B)	358
<b>East Java,</b>	
immunological and clinical features of smear-positive pulmonary tuberculosis in. Kardjito, T. and Grange, J. M. . . . . .(A)	283
<b>Edema,</b>	
of extremities. McDUGALL, A. C. . . . . .(C)	91
of hands and feet. CRAWFORD, C. L. . . . . .(C)	90
<b>Electron microscopic study,</b>	
and biochemical studies of the peribacillary substance of <i>M. leprae</i> . Fukunikshi, Y., <i>et al.</i> . . . . .(A)	499
on <i>M. leprae</i> in nerve lesions in lepromatous leprosy. Choe, J. and Kim, W. I. . . . .(A)	369
<b>Enna, Carl D.,</b>	
retirement of. . . . . .(N)	265
<b>ELISA test(s),</b>	
a study of antibodies to <i>M. tuberculosis</i> in the IgG, IgA, and IgM classes in tuberculosis, sarcoidosis, and Crohn's disease. Grange, J. M., <i>et al.</i> . . . . .(A)	144

- an inexpensive, portable battery-operated photometer for the reading of, in microtitration plates. Rook, G. A. and Cameron, C. H. ....(A) 478
- use of, to screen for anti-thymocyte and anti- $\beta_2$ -microglobulin, in leprosy and SLE. Bahr, G. M., *et al.* ....(A) 273
- EMR Newsletter,**  
WHO Eastern Mediterranean Region, new publication begins. ....(N) 264
- Epidemiology,**  
immunogenetics of susceptibility to leprosy, tuberculosis and leishmaniasis, an epidemiological approach. FINE, P. E. M. ....(E) 437
- of coronary artery disease among Hansen's disease patients. Mouloupoulos, S. D., *et al.* ....(A) 130
- study of leprosy through school survey in Surat District (South Gujarat). Bhavsar, B. S. and Mehta, N. R. ....(A) 140
- Enzyme(s),**  
activity in cultured macrophages infected with some species of mycobacteria. Katoh, M. and Matsuo, Y. ....(A) 507
- linked immunosorbent assay using arabinomannan from *M. smegmatis*: results in patients with tuberculosis and leprosy and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. ....(A) 506
- occurrence of  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GT) in mycobacteria. SHETTY, K. T., *et al.* ....(O) 49
- occurrence of superoxide dismutase in *M. leprae* grown on armadillo liver. Kusonose, E., *et al.* ....(A) 278
- superoxide dismutase in cell-free extracts from *M. leprae* grown on armadillo liver. Kusonose, E., *et al.* ....(A) 373
- Erythema nodosum leprosum (ENL),**  
clofazimine and dapsone, a combination therapy in. Dutta, R. D. ....(A) 122
- histology of, variant forms in New Guineans and other ethnic groups. Ridley, D. S., *et al.* ....(A) 371
- jaundice occurring as a complication of. Kumar, B., *et al.* ....(A) 129
- renal involvement as related to. Bajaa, A. K., *et al.* ....(O) 37
- ultrastructure of nerve in. Anthony, J., *et al.* ....(A) 273
- Ethiopia,**  
agreement between Ministry of Health and All Africa Leprosy and Rehabilitation Training Centre (ALERT) for training in leprosy. ....(N) 97
- ALERT designated as a WHO Collaborating Centre for Training. ....(N) 349
- association of pregnancy and leprosy: new cases, relapse of cured patients, and deterioration in patients on treatment during pregnancy and lactation, a prospective study of 154 pregnancies in 147 Ethiopian women. Duncan, M. E., *et al.* ....(A) 471
- self-administration of dapsone by leprosy patients in. Ellard, G. A., *et al.* ....(A) 469
- Europe,**  
recent research activities in mycobacteriology in. Grange, J. M. ....(A) 278
- Eye(s),**  
an assessment of the usefulness and acceptability of eye shields under field conditions. Verma, N. ....(A) 475
- blindness due to leprosy. Radnakrishnan, N. and Albert, S. ....(A) 473
- cataract surgery in management of late complications of lepromatous leprosy in South Korea. ffytche, T. J. ....(A) 365
- complications of, in leprosy, in Prakasam District (Andhra Pradesh). Reddy, S. C., *et al.* ....(A) 367
- dapsone-induced optic atrophy and motor neuropathy. Homeida, M., *et al.* ....(A) 361
- influence of untreated chronic plastic iridocyclitis on intraocular pressure in leprosy patients. Brandt, F., *et al.* ....(A) 364
- ocular findings in leprosy patients in an institution in Nepal. Malla, O. K., *et al.* ....(A) 366
- ocular involvement in leprosy. Acharya, B. P. ....(A) 271
- prevalence of ocular manifestations of leprosy in Port Moresby, Papua New Guinea. Dethlefs, R. ....(A) 365
- role of iris changes as a cause of blindness in lepromatous leprosy. ffytche, T. J., *et al.* ....(A) 365

<b>Experimental leprosy,</b>		
prothionamide and prothionamide-S-oxide in. MATSUO, Y., <i>et al.</i> . . . . .(O)		302
<b>Face,</b>		
lepromatous leprosy, clinically localized to one-half of the face. MASCARO, J. M., <i>et al.</i> . . . . .(O)		315
reconstructive surgery of deformities in, in leprosy. Teixeira, A. C. . . . .(A)		283
<b>Feet,</b>		
radiological studies on changes of, in calcaneus trabecula in leprosy. Yamamoto, Y. . .(A)		368
surgery of foot drop in leprosy by tibialis posterior transfer. Malaviya, G. N. . . . .(A)		485
<b>Fernandez reaction,</b>		
histology, an appraisal of. THOMAS, J., <i>et al.</i> . . . . .(O)		1
reaction in unaffected non-contact children and adolescents tested with human antigen and different concentrations of armadillo antigen in 3 double blind trials. Bechelli, L. M., <i>et al.</i> . . . . .(A)		364
<b>Fibers,</b>		
unmyelinated, degeneration and regeneration of, in experimental leprosy neuropathy. SHETTY, V. P. and ANTIA, N. H. . . . . .(O)		324
<b>Fingers,</b>		
in non-lepromatous leprosy. CRAWFORD, C. L. . . . . .(C)		90
<b>Fluorescent staining procedure,</b>		
for determining the viability of mycobacterial cells. Kvach, J. T. and Veras, J. R. . . .(A)		502
<b>Foot pad(s),</b>		
effects of infection with <i>M. marinum</i> and <i>M. leprae</i> on natural killer cell activity as a manifestation of cell mediated immunity to local infection. Krahenbuhl, J. L. and Humphres, R. C. . . . . .(A)		512
of Swiss mice, inoculated with <i>M. leprae</i> , description of morphological changes in unmyelinated fibers. SHETTY, V. P. and ANTIA, N. H. . . . . .(O)		324
<b>France,</b>		
Sixth Scientific Meeting of the Association des Epidémiologistes de Langue Française (ADELF). . . . . .(N)		99
<b><math>\gamma</math>-glutamyl transpeptidase</b>		
activity in <i>M. leprae</i> and other mycobacteria. SHETTY, K. T., <i>et al.</i> . . . . .(O)		49
<b>Germany, Federal Republic of,</b>		
German Leprosy Relief Association (DAHW) appoints Wilhelm Dewald as General Manager. . . . . .(N)		349
World Leprosy Day. . . . . .(N)		99
<b>Guadeloupe (F.W.I.),</b>		
detection of leprosy in a district of. Millan, J. . . . . .(A)		141
<b>Hand(s),</b>		
deformity of thumb in ulnar paralysis. Palande, D. D. and Gilbie, S. G. . . . . .(A)		377
relative tension and potential excursion of muscles in. Brand, P. W., <i>et al.</i> . . . . .(A)		484
surgical treatment for leprotic intrinsic hand muscle paresis. Zheng, T. S. . . . . .(A)		142
<b>Hemolysis,</b>		
in leprosy patients. SRITHARAN, V., <i>et al.</i> . . . . .(O)		307
<b>Hepatitis,</b>		
— B antigen and antibody in Papua New Guinea. Ree, G. H. and Talanou, M. T. . . . .(A)		478
<b>Histiocytoma,</b>		
leprosy. Misra, R. C. . . . . .(A)		133
<b>Histoid leprosy,</b>		
clinical and experimental observations. Li Wenzhong, <i>et al.</i> . . . . .(A)		367
Wade's spindle shaped leproma cells arising from perineurium, a link with. Gaulier, A. . . . . .(A)		476
<b>Histology,</b>		
correlations between clinical elements and, in leprosy. Husser, J. A., <i>et al.</i> . . . . .(A)		366
course of reactions in borderline leprosy and their outcome. RIDLEY, D. S. and RADIA, K. B. . . . . .(O)		383

- histopathological findings of serial preparation including the total length of nerve  
 extremitas thoracica in leprosy. Koya, G., *et al.* .....(A) 477
- histopathological re-examination of 50 discharged patients. Yao-De, Z. ....(A) 368
- of ENL, variant forms in New Guinea and other ethnic groups. Ridley, D. S., *et al.* ..(A) 371
- of Fernandez reaction. THOMAS, J., *et al.* .....(O) 1
- History,**  
 how old is leprosy? Browne, S. G. ....(A) 468
- Hormones,**  
 changes in, in human leprosy. Ree, G. H., *et al.* .....(A) 473
- profile in lepromatous leprosy. ROLSTON, R., *et al.* .....(O) 31
- Hypersensitivity,**  
 dapsone. Tomecki, K. J., *et al.* .....(A) 126
- delayed type, development of, in C57B1 and BALB/c mice, effect of cyclophosphamide treatment on. Alexander, J. ....(A) 279
- , failure to induce in long-term treated lepromatous leprosy patients. Smelt, A. H., *et al.* .....(A) 478
- , to mycobacterial antigens. Lovik, M. and Closs, O. ....(A) 477
- , to *M. leprae*, induction of in healthy individuals. Smelt, A. H., *et al.* .....(A) 479
- ILEP (International Federation of Anti-Leprosy Associations),**  
 appeal on World Leprosy Day. ....(N) 99
- collaboration with ILA for XII International Leprosy Congress, 1983. ....(N) 461
- Immune complex(es),**  
 circulating, and tissue, in leprosy. SEHGAL, S. and KUMAR, B. ....(O) 294
- , detected by Clq solid phase assay in leprosy. NUTI, M., *et al.* .....(O) 27
- Immune response,**  
 humoral, studies on, in leprosy. Yokoyama, M., *et al.* .....(A) 272
- , in mice, assessment of, immune response to *M. lepraemurium*. Navalkar, R. G. and Kanchana, M. V. ....(A) 280
- , further studies on the assessment of immune response to *M. leprae*. ....(A) 280
- Immunity,**  
 BCG induced, to *M. leprae*, in mice. Ganguly, N. K., *et al.* .....(A) 280
- protective, delayed type hypersensitivity to mycobacterial antigens without, a failure to produce the right specificity or the right type of immune reaction. Lovik, M. and Closs, O. ....(A) 477
- , preliminary immunological studies in search of correlates of, carried out on Iranian leprosy patients and their families. Stanford, J. L., *et al.* .....(A) 277
- Immunity, cell mediated (CMI),**  
 a study of, in leprosy. Dubey, G. K. ....(A) 369
- immunological status of maculoanesthetic leprosy: leucocyte migration inhibition test as a measure of. Rao, S. S. L. and Rao, P. R. ....(A) 473
- in cutaneous tuberculosis. Sengupta, L. K., *et al.* .....(A) 488
- quantitative DNCB epicutaneous sensitization in leprosy patients and controls. Sivamani, S., *et al.* .....(A) 272
- to local infection, manifestation of; effects of foot pad infection with *M. marinum* and *M. leprae* on natural killer cell activity. Krahenbuhl, J. L. and Humphres, R. C. ..(A) 512
- Immunogenetics,**  
 of susceptibility to leprosy, tuberculosis, and leishmaniasis, an epidemiological perspective. FINE, P. E. M. ....(E) 437
- Immunology,**  
 immunological aspects of leprosy. Harboe, M. and Closs, O. ....(A) 477
- recognition, immunological, and effector mechanisms in infectious diseases. WHO. ....(A) 275
- study on leprosy, T and B lymphocytes of peripheral blood. Bao-Hong Ji. ....(A) 274
- Indeterminate leprosy,**  
 an experience on treatment of five intractable cases of. Sohn, J. S., *et al.* .....(A) 365
- should . . . ever be diagnosed? PETTIT, J. H. S. ....(C) 95
- India,**  
 Acworth Leprosy Hospital, Tenth Workshop on Leprosy. ....(N) 351

—, Society for Research, Rehabilitation, and Education in Leprosy issues ten year report. ....(N)	261
All India Leprosy Workers' Conference. ....(N)	350
an analysis into the trends of reconstructive surgery in Gudiyatham Taluk, a leprosy control area. Jesudasan, S., <i>et al.</i> ....(A)	376
Asian Seminar on Vocational Rehabilitation of Leprosy Patients. ....(N)	352
Association of Microbiologists of India and Foundation for Medical Research sponsors international symposium on <i>M. leprae</i> . ....(N)	262
Bombay Leprosy Project 1979 annual report. ....(N)	100
Central JALMA Institute for Leprosy 1979 annual report. ....(N)	101
Consensus Conference on Classification of Leprosy. ....(N)	103
deformities in leprosy patients of Indian Armed Forces treated/reviewed at Military Hospital, Agra. Tiwari, V. D. and Mehta, R. P. ....(A)	475
Gandhi Memorial Leprosy Foundation summary of 1979 activities. ....(N)	101
Hemerijckx Government Leprosy Centre Silver Jubilee. ....(N)	103
Hind Kusht Nivaran Sangh, Andhra Pradesh Branch, and A.M.G. India International, second seminar on leprosy. ....(N)	349
—, activities of. ....(N)	102
—, annual general meeting. ....(N)	351
—, annual report. ....(N)	101
honors to three outstanding leprologists. ....(N)	462
incidence of glucose-6-phosphate dehydrogenase deficiency in a hospital population of Delhi. Madan, N., <i>et al.</i> ....(A)	487
Indian Association of Leprologists. ....(N)	102
XII International Leprosy Congress, call for abstracts. ....(N)	461
—, to be held 21–26 November 1983 in New Delhi. ....(N)	352
leprosy in, an analysis of 4 years of O.P.D. data. Mani, M. Z. and Mathew, M. ....(A)	483
— Jaipur. A clinical and epidemiological study. Mathur, N. K., <i>et al.</i> ....(A)	483
The Leprosy Mission. ....(N)	350
—, in Southern Asia. ....(N)	103
<i>National Leprosy Organisation</i> publication. ....(B)	116
prevalence of leprosy, among inpatients in general hospitals, a survey in Bombay. Ganapati, R., <i>et al.</i> ....(A)	281
—, among slum dwellers. Marshall, J. T., <i>et al.</i> ....(A)	281
Prime Minister Indira Gandhi calls for war on leprosy. ....(N)	352
Schieffelin Leprosy Research and Training Centre, 1982 course schedule. ....(N)	461
—, Karigiri Neuritis Workshop. ....(N)	99
—, Silver Jubilee. ....(N)	351
survey of eye complications in leprosy in Prakasam District (Andhra Pradesh). Reddy, S. C., <i>et al.</i> ....(A)	367
Tamil Nadu State Branch State Council Meeting. ....(N)	351
IX Workshop on Leprosy and 10th anniversary, Acworth Leprosy Hospital Society for Research, Rehabilitation and Education. ....(N)	103
<b>Indonesia,</b>	
leprosy in. Harahap, M. ....(A)	483
<b>INTERNATIONAL JOURNAL OF LEPROSY,</b>	
acknowledgment. ....(—)	146
.....(—)	285
.....(—)	382
.....(—)	533
reviewers, list of. ....(—)	467
statement of financial condition. ....(—)	379
statement of ownership, management and circulation. ....(—)	519
<b>International Leprosy Association,</b>	
at 50 years. LECHAT, M. F. ....(E)	60
formation of. COCHRANE, R. G. ....(E)	67
organization and membership. ....(—)	519
presidents of. ....(—)	72

<b>International Leprosy Congress, XII,</b>		
first intimation. . . . .	(N)	460
call for abstracts. . . . .	(N)	461
ILEP collaboration. . . . .	(N)	461
<b>Iran,</b>		
preliminary immunological studies in search of correlates of protective immunity carried out on families in. Stanford, J. L., <i>et al.</i> . . . . .	(A)	277
<b>Ireland,</b>		
UNESCO Science Prize for 1980 awarded to group from Laboratories of the Medical Research Council of Ireland. . . . .	(N)	262
<b>Italy,</b>		
European Leprosy Symposium. . . . .	(N)	262
ILEP, 35th meeting of the Medical Commission in Rome. . . . .	(N)	462
Pope John Paul II meets with ILEP members. . . . .	(N)	104
symposium on leprosy in light-skinned people. . . . .	(N)	462
<b>Japan,</b>		
Japanese leprosy conference, Tokyo. . . . .	(N)	104
Miyako Islands, FLA-ABS and lepromin tests in school children. Immuno-epidemiological studies on subclinical infection with <i>M. leprae</i> . . . . .	(A)	503
U.S.-Japan Cooperative Medical Science Program, Sixteenth Joint Leprosy Conference, Bethesda, Maryland, 13-14 July 1981. . . . .	(—)	490
<b>Jaundice,</b>		
occurring as a complication of ENL (a report of cases). Kumar, B., <i>et al.</i> . . . . .	(A)	129
<b>Kenya,</b>		
pulmonary tuberculosis in, a third study of case-finding methods. Nsanzumuhire, H., <i>et al.</i> . . . . .	(A)	483
<b>Kirchheimer, Dr. W. F.,</b>		
personal. . . . .	(N)	464
<b>Korea,</b>		
cataract surgery in the management of late complications of lepromatous leprosy in South Korea. ffytche, T. J. . . . .	(A)	365
<b>Larynx,</b>		
a clinico-pathological study of laryngeal lesions in 30 cases of leprosy. Gupta, J. C., <i>et al.</i> . . . . .	(A)	129
<b>Leiker, Dr. Derek Luitjen,</b>		
personal. . . . .	(N)	264
<b>Leishmaniasis,</b>		
immunogenetics of susceptibility to leprosy, tuberculosis, and . . . an epidemiological perspective. FINE, P. E. M. . . . .	(E)	437
<b>Leonard Wood Memorial,</b>		
conference on leprosy in Manila, Philippine Islands, 9-23 January 1931. WADE, H. H. and GESHUE-TAYLOR, G. . . . .	(E)	64
new leadership. . . . .	(N)	465
<b>Lepromatous leprosy,</b>		
as a model of Schwann cell pathology and lysosomal activity. Dastur, D. K. and Porwal, G. L. . . . .	(A)	369
clinically localized to one-half of the face. MASCARO, J. M., <i>et al.</i> . . . . .	(O)	315
clofazimine (Lamprene, B663) in the treatment of. BROWNE, S. G., <i>et al.</i> . . . . .	(O)	167
controlled trial to compare the therapeutic effects of dapsona in combination with daily or once-daily rifampin. OPROMOLLA, D. V. A. . . . .	(O)	393
dapsona-induced hypohaptoglobinemia in. SRITHARAN, V., <i>et al.</i> . . . . .	(O)	307
evidence for <i>in situ</i> activation of suppressor T cells. Mehra, V., <i>et al.</i> . . . . .	(A)	515
failure to induce delayed-type hypersensitivity to <i>M. leprae</i> in long-term treated patients. Smelt, A. H. M., <i>et al.</i> . . . . .	(A)	478
gonadal function in. Shilo, S., <i>et al.</i> . . . . .	(A)	474

effect of single dose (1500 mg) rifampin on infectivity of patients with.	Girdhar, B. K., <i>et al.</i> . . . . .(A)	123
hormone profile in.	ROLSTON, R., <i>et al.</i> . . . . .(O)	31
impairment of immunoregulatory control over B lymphocyte.	Bullock, W. E., <i>et al.</i> . .(A)	515
intra-neural ceroid-like pigment following treatment with clofazimine (B663; Lam- prene).	McDougall, A. C. and Jones, R. L. . . . .(A)	362
<i>in vivo</i> and <i>in vitro</i> effects of levamisole on patients with.	SHER, R. . . . .(O)	159
light and electron microscopic study on <i>M. leprae</i> in nerves.	Choe, J. and Kim, W. I. (A)	369
multiple drug therapy—a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH, and thiacetazone in.	Kundu, S. K., <i>et al.</i> . .(A)	362
neutrophil chemotactic responses in.	Wahba, A., <i>et al.</i> . . . . .(A)	136
polar, adherent suppressor cells in.	Ridel, P. R., <i>et al.</i> . . . . .(C)	91
presenting as orchitis.	Akhtar, M., <i>et al.</i> . . . . .(A)	127
renal functional status in.	BAJAJ, A. K., <i>et al.</i> . . . . .(O)	37
—.	Sriharan, V., <i>et al.</i> . . . . .(A)	474
serological and immunohistological studies on.	Kano, K., <i>et al.</i> . . . . .(A)	370
study of percutaneous renal biopsy in.	Gupta, S. C., <i>et al.</i> . . . . .(A)	369
subpolar. . . . a histologic and ultrastructural study of a patient.	Sanabria Negrin, J. G., <i>et al.</i> . . . . .(A)	135
treatment of, with combination of rifampin and isoprodian.	Colin, M. and de Montaigne, E. . . . .(A)	269
—.	with BCG, Villa, S. Z., <i>et al.</i> . . . . .(A)	480
Wade's histoid.	Rampure, A. M. and Bhargava, M. K. . . . .(A)	134
with rifampin 1200 mg once monthly, daily Lamprene®, and dapsone in treatment of refractory patients with.	PAUL, S. and ROSE, E. T. . . . .(C)	342
<b>Lepromin,</b>		
antigenic analysis of, assessment of Dharmendra antigen.	Sinha, S., <i>et al.</i> . . . . .(A)	276
-A-BCG, inoculation of, in cases that are negative to three successive tests.	Tarabini-Castellani, G., <i>et al.</i> . . . . .(A)	480
BCG vaccination and . . . -A administered contemporaneously seen in a separately positive association.	Tarabini-Castellani, G., <i>et al.</i> . . . . .(A)	480
double blind trials to study the . . . scar in leprosy patients and in children and ado- lescent non-contacts, tested with human antigen and different concentrations of armadillo antigen.	Bechelli, L. M., <i>et al.</i> . . . . .(A)	363
early Fernandez reaction in unaffected noncontact children and adolescents tested with human antigen and different concentrations of armadillo antigen in double blind trials.	Bechelli, L. M., <i>et al.</i> . . . . .(A)	364
granulomatous response of leprosy patients to . . . and killed BCG.	Han, S. H. . . . .(A)	476
influence of sulfone therapy on . . . reaction.	Ramu, G., <i>et al.</i> . . . . .(A)	126
Mitsuda reaction, comparative study with integral human and armadillo . . . , in 50 patients with leprosy.	Zambrano, T., <i>et al.</i> . . . . .(A)	368
Mitsuda test, with lepromin A, in healthy vaccinated cases who were not vaccinated with the anti-tuberculosis BCG.	Tarabini-Castellani, G., <i>et al.</i> . . . . .(A)	479
—, in cases pre-treated for 6 months with a mixture of lepromin-A and BCG.	Tarabini-Castellani, G., <i>et al.</i> . . . . .(A)	479
reaction, early.	THOMAS, J., <i>et al.</i> . . . . .(O)	1
-reaction in child contacts of leprosy patients and non-contact children in Chengal- pattu District, Tamil Nadu.	Ramu, G., <i>et al.</i> . . . . .(A)	141
recommended safety requirements for the preparation of, WHO memorandum.	Bloom, B. R., <i>et al.</i> . . . . .(A)	128
results of the . . . test using human (H) and armadillo lepromins.	Tarabini-Castellani, G., <i>et al.</i> . . . . .(A)	136
<b>Leprosy,</b>		
<i>A Guide to Leprosy Control.</i>	World Health Organization. . . . .(B)	113
age of onset.	Guha, P. K., <i>et al.</i> . . . . .(A)	281
an unusual factor-X inhibitor in.	. . . . .(A)	366
—and syphilis, a case report.	Nsibambi, J. K. . . . .(A)	473
atlas of information on, published by the Damien Foundation.	. . . . .(N)	97
bacterial persistence in.	TOMAN, K. . . . .(O)	205

blindness due to. Radnakrishnan, N. and Albert, S. . . . .	(A)	473
changing attitudes to. Middle East Health Supply and Service. . . . .	(A)	120
chemotaxis in. Martínez-Palacios, B. N. . . . .	(A)	276
circulating immune complexes in. NUTI, M., <i>et al.</i> . . . . .	(O)	27
Clq solid phase assay in. NUTI, M., <i>et al.</i> . . . . .	(O)	27
complement profile in. Kumar, B., <i>et al.</i> . . . . .	(A)	132
control of, a study of DDS test in urine. Yo, Y. H. . . . .	(A)	362
—, chimeras and possibilities. Browne, S. G. . . . .	(A)	120
—, role of school survey in. Chandra, S., <i>et al.</i> . . . . .	(A)	482
decline of, in China. SKINSNES, O. K. . . . .	(C)	341
deformities in patients of Indian Armed Forces treated/reviewed at Military Hospital, Agra. Towari, V. D. and Mehta, R. P. . . . .	(A)	475
detection of, prior to appearance of clinical symptoms with new blood test. REICH, C. V., <i>et al.</i> . . . . .	(O)	21
diabetic status in. Nigam, P., <i>et al.</i> . . . . .	(A)	473
—, down but not out. Garfield, E. . . . .	(A)	120
genetic diathesis for. Guha, P. K., <i>et al.</i> . . . . .	(A)	482
histocompatibility antigens of. Park, E. S., <i>et al.</i> . . . . .	(A)	376
hormonal changes in. Ree, G. H., <i>et al.</i> . . . . .	(A)	473
how old is . . . ? Browne, S. G. . . . .	(A)	468
hypothesis: do phases of immunosuppression during a <i>M. leprae</i> infection determine the spectrum of? Stoner, G. L. . . . .	(A)	372
immunogenetics of susceptibility to . . . , tuberculosis, and leishmaniasis. an epi- demiological perspective. FINE, P. E. M. . . . .	(E)	437
immunology of. Navalkar, R. G. . . . .	(A)	134
in an albino. Pannikar, V. K. and Arunthathi, S. . . . .	(A)	272
in Indonesia. Harahap, M. . . . .	(A)	483
in Murcia Province, Spain. Castro Diez, M. C., <i>et al.</i> . . . . .	(A)	281
knowledge about, among leprosy patients. Raj, V., <i>et al.</i> . . . . .	(A)	377
<i>Leprosy in the Dark Skin</i> . Leiker, D. L. . . . .	(B)	116
<i>Leprosy in Tropical Australia</i> . Hargrave, J. C. and Jones, E. R. . . . .	(B)	115
<i>Leprosy-Tuberculosis Eradication</i> . Freerksen, E. and Rosenfeld, M. . . . .	(B)	114
looking out for. Browne, S. G. . . . .	(A)	364
low serotonin uptake by platelets, prevention of. SZABADOS, L., <i>et al.</i> . . . . .	(O)	42
mononuclear cell series in, an ultrastructural report. Ridley, M. J. . . . .	(A)	371
natural suppressor cells in. Nath, I. . . . .	(A)	134
numerical changes in T cell subsets in. Izumi, S., <i>et al.</i> . . . . .	(A)	275
patients with and family contacts of, results of an enzyme-linked immunosorbent assay using arabinomannan from <i>M. smegmatis</i> . Miller, R. A. and Buchanan, T. M. . . . .	(A)	506
psychological reactions to. Behere, P. B. . . . .	(A)	376
psychosomatics of. Ree, G. H. . . . .	(A)	121
radiological studies on changes in calcaneus trabecula in. Yamamoto, Y. . . . .	(A)	368
respiratory reflexes in. MALIK, S. K., <i>et al.</i> . . . . .	(C)	94
rheumatic manifestations of. Albert, D. A., <i>et al.</i> . . . . .	(A)	127
rising incidence of, in the U.S.A. Levis, W. R. and Hedrick, J. L. . . . .	(A)	376
serum atypical pseudocholesterase and. Navarette, J. I., <i>et al.</i> . . . . .	(A)	141
serum lysozyme in. Naik, S. S. and Gurnani, S. . . . .	(A)	130
serum migration inhibitory activity in patients. Rea, T. H. and Yoshida, T. . . . .	(A)	516
serum protein in. Parvez, M., <i>et al.</i> . . . . .	(A)	130
studies on T cell subsets and functions in. Bach, M.-A., <i>et al.</i> . . . . .	(A)	475
study of estimation of serum alpha-1-antitrypsin in various forms of. Singhal, A. L., <i>et al.</i> . . . . .	(A)	474
survey on incidence of in Geoje Island. Park, K. W. . . . .	(A)	376
trends of reconstructive surgery in Gudiyatham Taluk, a control center. Jesudasan, S., <i>et al.</i> . . . . .	(A)	376
update on. Hargrave, J. C. . . . .	(A)	359
<b>Lesions,</b>		
evolution of nasal mucosal . . . in leprosy. Mehta, L., <i>et al.</i> . . . . .	(A)	271
isolated plantar and palmar . . . of tuberculoid leprosy. Laja, A. O. and Soyinka, F. . . . .	(A)	271

<b>Leukocyte,</b>		
migration inhibition test of, in leprosy patients across the spectrum of leprosy.		
Sivamani, S., <i>et al.</i> . . . . .	(A)	135
<b>Levamisole,</b>		
<i>in vivo</i> and <i>in vitro</i> effect of, on patients with lepromatous leprosy. SHER, R., <i>et al.</i> . . . . .	(O)	159
rifampicina asociada a. Wilkinson, F. and Liturri, M. . . . .	(A)	127
therapeutic trial of, in leprosy patients. Kim, W. S. and Cinn, Y. W. . . . .	(A)	361
<b>Lewis rat(s),</b>		
neonatally thymectomized, relationship between T cell population in, and susceptibility to infection with <i>M. leprae</i> . FIELDSTEEL, A. H., <i>et al.</i> . . . . .	(O)	317
<b>Liberia,</b>		
Conference on Integration of Leprosy and Tuberculosis Services. . . . .	(N)	104
<b>Libya,</b>		
leprosy in. Malhotra, Y. K. and Kanwar, A. J. . . . .	(A)	140
<b>Lipids,</b>		
—, and lipoprotein profiles in leprosy. DEVI, C. S., <i>et al.</i> . . . . .	(C)	344
constituents of <i>M. leprae</i> isolated from experimentally infected armadillos. Asselineau, C., <i>et al.</i> . . . . .	(A)	372
detection of mycobacterial . . . in skin biopsies from leprosy patients. YOUNG, D. B. (O)		198
<b>Lithium acetate extraction,</b>		
procedure to obtain extract containing <i>M. leprae</i> specific antigen. HARBOE, M. and CLOSS, O. . . . .	(C)	84
reply to Dr. Harboe's and Dr. Closs's Letter to the editor. BUCHANAN, T. M., <i>et al.</i> . . . . .	(C)	88
<b>Liver,</b>		
damage, a study of, in leprosy patients during lepra reaction. Kim, D. K. . . . .	(A)	366
in leprosy, functional changes. Robins, K., <i>et al.</i> . . . . .	(A)	130
lesions in reaction states in leprosy. Gharpuray, S. M., <i>et al.</i> . . . . .	(A)	472
<b>Lymph node(s),</b>		
aspiration cytology of, in leprosy. GUPTA, S. K., <i>et al.</i> . . . . .	(O)	9
disorders, in lepromatous patients. Piva, J. R. and de Perez Nardini, S. . . . .	(A)	134
<b>Lymphocytes,</b>		
B, impairment of immunoregulatory control over function of, in lepromatous leprosy.		
Bullock, W. E., <i>et al.</i> . . . . .	(A)	515
human, <i>in vitro</i> stimulation of, with mycobacterial antigens. WRIGHT, E. P. and RANGARAJAN, R. . . . .	(C)	455
selective loss of <i>M. leprae</i> responsiveness of circulating . . . in primary neuritic leprosy. Nath, I., <i>et al.</i> . . . . .	(A)	370
status of circulating "T" lymphocyte population in leprosy. . . . .	(A)	135
study on T and B, of peripheral blood, immunological study of leprosy. Bao-Hong Ji. (A)		274
suppressive effect of <i>M. leprae</i> on the <i>in vitro</i> proliferative responses of, from patients with leprosy. Nath, I. and Singh, R. . . . .	(A)	133
<b>Lysosome(s),</b>		
lepromatous leprosy as a model of Schwann cell pathology and lysosomal activity.		
Dastur, D. K. and Porwal, G. L. . . . .	(A)	369
<b>Macrophage(s),</b>		
—, culture from untreated leprosy cases. Veliath, A. J., <i>et al.</i> . . . . .	(A)	137
—, cultured, infected with some species of mycobacteria, lysosomal enzyme activity in. Katoh, M. and Matsuo, V. . . . .	(A)	507
uptake of <sup>3</sup> H-thymidine in <i>M. leprae</i> inoculated mouse . . . cultures as a rapid indicator of bacillary viability. SATHISH, M. and NATH, I. . . . .	(O)	187
<b>Malaria,</b>		
cloning of naturally occurring mixed infections of parasites of. Rosario, V. . . . .	(A)	378
<b>Malaysia,</b>		
Malaysian Leprosy Relief Association. . . . .	(N)	104
<b>Mangabey monkey (<i>Cercocebus torquatus atys</i>),</b>		
leprosy in. Meyers, W. M., <i>et al.</i> . . . . .	(A)	500

<b>Mexico,</b>		
leprosy workshop held in Mexicali. . . . .	(N)	352
XVI meeting of Mexican Leprosy Society. . . . .	(N)	352
two national associations on leprosy. . . . .	(N)	104
<b>Mice,</b>		
ATP content harvested from (nude), using firefly bioluminescence method. DHOPLE, M. and HANKS, J. H. . . . .	(O)	57
assaying dapsone in diets of. Ellard, G. A. . . . .	(A)	269
C57B1 and BALB/c, effect of cyclophosphamide treatment on course of <i>M. lepraemurium</i> infection. Alexander, J. . . . .	(A)	279
intact mouse as a host for the detection of small numbers of viable <i>M. leprae</i> in the presence of large numbers of heat-killed <i>M. leprae</i> . Fieldsteel, A. H. . . . .	(A)	490
lack of correlation between antigen-specific cellular reactions and resistance to <i>M. lepraemurium</i> infection in. Curtis, J., <i>et al.</i> . . . .	(A)	482
normal, thymectomized, irradiated and thymus transplanted <i>M. leprae</i> infection in. Kaur, S., <i>et al.</i> . . . .	(A)	482
nude, study of chemotherapy of leprosy with. Kohsaka, K., <i>et al.</i> . . . .	(A)	508
survival of BALB/c mice after intraperitoneal infection with <i>M. lepraemurium</i> . Levy, L., <i>et al.</i> . . . .	(A)	138
viability of <i>M. leprae</i> after multiplication in. . . . .	(A)	139
<b>Mitsuda reaction,</b>		
histology and significance of. Thomas, J., <i>et al.</i> . . . .	(A)	277
<b>Morocco,</b>		
fifth meeting of Association des Leprologues de Langue Française. . . . .	(N)	463
<b>Morphological Index (MI),</b>		
choice of slit smears for study of BI and MI. Kaur, S., <i>et al.</i> . . . .	(A)	129
<b>Muscle(s),</b>		
striated, pathologic changes in, in leprosy. Kaur, S., <i>et al.</i> . . . .	(A)	275
relative tension and potential excursion of, in forearm and hand. Brand, P., <i>et al.</i> . . . .	(A)	484
<b>Mycobacteria,</b>		
antigenic relationships between <i>M. leprae</i> and other . . . defined by absorbed leprosy sera and monoclonal antibodies. Gillis, T. P. and Buchanan, T. M. . . . .	(A)	504
comparison of 22 species of, by immunodiffusion against an absorbed reference leprosy serum. Gillis, T. P., <i>et al.</i> . . . .	(A)	287
environmental, predetermination of efficacy of BCG. Stanford, J. L., <i>et al.</i> . . . .	(A)	277
failure to detect <i>o</i> -diphenoloxidase in cultivable mycobacteria obtained from feral armadillos. Prabhakaran, K., <i>et al.</i> . . . .	(A)	281
fluorescent staining procedure for determining viability of cells of. Kvach, J. T. and Veras, J. R. . . . .	(A)	502
killed, immunogenicity of. Rook, G. A. W. . . . .	(A)	276
lysosomal enzyme activity in cultured macrophages infected with some species of. Katoh, M. and Matsuo, Y. . . . .	(A)	507
multivariate analysis of the activity of rifamycins against rapidly growing . . . to define an <i>in vitro</i> screening model for their activity against <i>M. leprae</i> . Pattyn, S. R. and Hebrant, F. . . . .	(A)	373
<i>Mycobacterial Diseases</i> , Grange, J. M. . . . .	(B)	114
nontuberculous, epidemiology of infection by, isolation of potentially pathogenic mycobacteria from aerosols. Wendt, S. L., <i>et al.</i> . . . .	(A)	284
profiles of skin test reactivity to antigens of various species of, in human population and in experimental infections. Vandiviere, H. M., <i>et al.</i> . . . .	(A)	284
<b><i>Mycobacterium avium-intracellulare</i>,</b>		
rapid radiometric method for determining drug susceptibility of. Yangco, G. G., <i>et al.</i> (A)		378
<b><i>Mycobacterium chelonae</i>,</b>		
resistant cutaneous infection caused by. Fenske, N. A. and Millns, J. L. . . . .	(A)	283
<b><i>Mycobacterium leprae</i>,</b>		
adenosine triphosphate content in. DHOPLE, A. M. and HANKS, J. H. . . . .	(O)	57
a novel glycolipid from, possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. . . . .	(A)	504

antigenic relationships with other mycobacteria defined by absorbed leprosy sera and monoclonal antibodies. Gillis, T. P. and Buchanan, T. M. ....(A)	504
ATP content and other characteristics of. Dhople, A. M., <i>et al.</i> ....(A)	502
contamination of, by armadillo proteins, during its purification, quantitation and characterization. Quesada-Pascual, F., <i>et al.</i> ....(A)	506
cultivable precursors of <i>M. leprae</i> . Chatterjee, B. R. ....(A)	137
discharge of, in milk of leprosy patients. Girdhar, A., <i>et al.</i> ....(A)	472
effect of, on lymphocyte proliferation. Touw, J., <i>et al.</i> ....(A)	136
electron-microscopic and biochemical studies of peribacillary substance of. Fukunishi, Y., <i>et al.</i> ....(A)	499
evaluation of fluorescent microscopy for detection of. Hardas, U. and Lele, V. ....(A)	370
$\gamma$ -glutamyl transpeptidase activity in. SHETTY, K. T., <i>et al.</i> ....(O)	49
immuno-epidemiological studies with. FDA-ABS and lepromin tests in school children in the Miyako Islands. Abe, M., <i>et al.</i> ....(A)	503
immunogenicity of, effect of purification steps. Shepard, C. C., <i>et al.</i> ....(A)	371
inhibition of the incorporation of $^3\text{H}$ DOPA, by desoxyfructo-serotonin. Jayaraman, P., <i>et al.</i> ....(A)	124
intact mouse as a host for the detection of small numbers of viable . . . in the presence of large numbers of heat killed. Fieldsteel, A. H., <i>et al.</i> ....(A)	499
isolation and identification of mycolic acids in . . . and <i>M. lepraemurium</i> . KUSAKA, T., <i>et al.</i> ....(O)	406
paracrystalline inclusions in. David, H. L., <i>et al.</i> ....(A)	372
parameters influencing the <i>in vitro</i> growth of. PORTAELS, F. and PATTYN, S. R. ....(O)	194
persist, after introductory rifampin followed by dapsone therapy. Sreevasta, B. K., <i>et al.</i> ....(A)	470
relationship between T-cell population in neonatally thymectomized Lewis rats and susceptibility to infection with. FIELDSTEEL, A. H., <i>et al.</i> ....(O)	317
-specific antigen. HARBOE, M. and CLOSS, O. ....(C)	84
suppressive effect of, on the <i>in vitro</i> proliferative responses of lymphocytes from patients with leprosy. Nath, I. and Singh, R. ....(A)	133
viability of, after multiplication in mice. Welch, T. M., <i>et al.</i> ....(A)	139
<b><i>Mycobacterium lepraemurium</i>,</b>	
effect of vitamins on cultivation of, in axenic liquid medium and its implication in the culture of <i>M. leprae</i> . ....(A)	502
growth of, in cell-free liquid medium containing soluble starch: evaluation by generation time and morphological observation. Sengupta, U. and Nakamura, M. ....(A)	279
host-grown, energy coupling mechanisms in. Ishaque, M., <i>et al.</i> ....(A)	481
identification of, use of wall-bound mycolic acids. Young, D. B. ....(A)	279
isolation and identification of mycolic acids in <i>M. leprae</i> and. KUSAKA, T., <i>et al.</i> ....(O)	406
pedigreed stocks of, for cultivation and metabolic studies. Dhople, A. M. and Hanks, J. H. ....(A)	137
phospholipid deacylating activities in murine leprosy bacilli. Kushiwabara, Y., <i>et al.</i> ..(A)	373
relationship between length of bacilli and log phase of growth of, in cell-free liquid medium. Sengupta, U. and Nakamura, M. ....(A)	278
role of sulfhydryls in <i>in vitro</i> growth of. Dhople, A. M. and Hanks, J. H. ....(A)	278
<b><i>Mycobacterium marinum</i>,</b>	
effects of foot pad infection with . . . and <i>M. leprae</i> on natural killer cell activity as a manifestation of cell mediated immunity to local infection. Krahenbuhl, J. L. and Humphres, R. C. ....(A)	512
<b><i>Mycobacterium smegmatis</i>,</b>	
arabinomannan from, an enzyme-linked immunosorbent assay, results in patients with tuberculosis and leprosy and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. ....(A)	506
<b><i>Mycobacterium ulcerans</i>,</b>	
radiological abnormalities of the ileum associated with the use of clofazimine (Lamprene; B663) in the treatment of skin ulceration due to. de Bergcyck, E., <i>et al.</i> ... (A)	122
<b><i>Mycobacterium W</i>,</b>	
report on the biochemical analysis of. Katoch, V. M. ....(A)	481

- Mycobacterium X*,**  
 from lepromata cultivated in tetradecane-DMSO medium. Kato, L. ....(C) 93
- Mycolic acids,**  
 isolation and identification of, in *M. leprae* and *M. lepraemurium*. Kusaka, T., *et al.* (O) 406  
 wall-bound, use of, in identification of *M. leprae*. Young, D. B. ....(A) 279
- Nepal,**  
 leprosy care activities in. ....(N) 105  
 ocular findings in leprosy patients in an institution. Malla, O. K., *et al.* ....(A) 366
- Netherlands, The,**  
 availability of educational materials on "leprosy in the dark skin." ....(N) 109  
 Dr. D. L. Leiker awarded honorary doctorate by University of Amsterdam. ....(N) 264  
 the Leprosy Documentation Service established. ....(N) 463  
 request for back issues of the IJL by Erasmus University. ....(N) 463  
 vacancies for doctors, Netherlands Leprosy Relief Association. ....(N) 353
- Nerves,**  
 basic function of, in leprosy patients. Brandsma, W. ....(A) 470  
 biopsy in Hansen's disease: fundamentals and surgical technique. Rial, R. M. L. ....(A) 474  
 histopathological findings of serial preparation including the total length of extremities  
 thoracica in leprosy. Koya, G., *et al.* ....(A) 477  
 immunopathology of damage of, in leprosy. HILL-SMITH, I. ....(E) 223  
 intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with  
 clofazimine (B663, Lamprene). McDougall, A. C. and Jones, R. L. ....(A) 362  
 management of nerve abscess in leprosy. Bhagat, K. P., *et al.* ....(A) 128  
 peripheral, do antileprosy drugs reach *M. leprae* in? Boddington, J. and Stolz, E. ....(A) 269  
 radioisotope angiography with a gamma camera. Charosky, C. B., *et al.* ....(A) 470  
 selective loss of *M. leprae* responsiveness of circulating lymphocytes in primary  
 neuritic leprosy. Nath, I., *et al.* ....(A) 370  
 simple and neurological protocol for use in the study of leprosy. Charosky, C. B. ....(A) 484  
 ultrastructure of, in erythema nodosum leprosy (ENL). Anthony, J., *et al.* ....(A) 273
- Neuritis,**  
 leprous, vascular changes in leprosy and its role in the pathogenesis of. Chopra,  
 J. S., *et al.* ....(A) 471  
 treatment with thalidomide in steroid dependency and. Theophilus, S. ....(A) 126
- Neuropathy,**  
 electrophysiologic and histolytic studies in leprosy and some acrodystrophic neuro-  
 pathies. PANDYA, S. S. and CHULAWALA, R. G. ....(O) 398  
 experimental leprous, degeneration and regeneration of unmyelinated fibers in.  
 SHETTY, V. P. and ANTIA, N. H. ....(O) 324  
 motor, dapsone-induced optic atrophy and. Homeida, M., *et al.* ....(A) 361
- New Zealand,**  
 leprosy in Auckland. Lang, W. R. ....(A) 130  
 cat leprosy in, observations of. Thompson, E. J., *et al.* ....(A) 284
- Nigeria,**  
 Sixth International Conference on the Global Impacts of Applied Microbiology  
 (GIAM VI). ....(N) 106
- Norway,**  
 International Symposium on the Epidemiology of Leprosy. ....(N) 463
- Obituaries,**  
 Andrade, Roberto Nunez. Sau, Amado. ....(Ob) 83  
 Yu Chia-Chun. Skinsnes, O. K.; Hu, C. K. and Ye Gan-yun. ....(Ob) 84
- Pakistan,**  
 leprosy control activities in. ....(N) 106
- Papua New Guinea,**  
 hepatitis B antigen and antibody in leprosy patients in. Ree, G. H. and Talonu, M. T. (A) 478  
 histology of erythema nodosum leprosum, variant forms in New Guineans and other  
 ethnic groups. Ridley, D. S., *et al.* ....(A) 371

leprosy patients in, taking of their dapsone. Ree, G. H. and Taylor, V. E. ....(A)	126
ocular leprosy in. Ree, G. H. ....(A)	272
prevalence of ocular manifestations of leprosy in Port Moresby. Dethlefs, R. ....(A)	365
<b>Paraguay,</b>	
Dr. W. F. Kirchheimer given plaque of appreciation. ....(N)	464
<b>Patient compliance,</b>	
new method to monitor, under field conditions. ELISA inhibition technique for	
demonstration of sulfones in body fluids. Huikeshoven, H., <i>et al.</i> ....(A)	361
self-administration of dapsone by leprosy patients in Ethiopia. Ellard, G. A., <i>et al.</i> ... (A)	469
study on treatment of defaulters in leprosy at the outpatient clinic. Choi, S. R. ....(A)	365
use of dried blood to monitor. ELISA inhibition technique for the demonstration of	
sulfones in body fluids. Huikeshoven, H., <i>et al.</i> ....(A)	470
<b>Phytohaemagglutinin (PHA),</b>	
-induced transformation of peripheral blood lymphocytes in leprosy patients. ....(A)	131
<b>Philippines, The,</b>	
evaluation of a new blood test for its potential to indicate leprosy infection prior to	
appearance of clinical symptoms. REICH, C. V., <i>et al.</i> ....(O)	21
Leonard Wood Memorial Conference held in Manila, 9-23 January 1931, WADE, H. H.	
and GESHUE-TAYLOR, G. ....(E)	64
model for coordination of international donor activities with national governmental	
health services. Nalli, G. A. and Pearson, D. A. ....(A)	282
primary dapsone-resistant leprosy in Cebu. GUINTO, R. S., <i>et al.</i> ....(O)	427
Tenth International Congress on Tropical Medicine and Malaria ....(N)	106
<b>Platelets,</b>	
low serotonin uptake by. SZABADOS, L., <i>et al.</i> ....(O)	42
<b>Porphyrins,</b>	
a quantitative assay of, in leprosy patients. PAVITHARAN, P., <i>et al.</i> ....(O)	311
<b>Pregnancy,</b>	
association of with leprosy: new cases, relapse of cured patients and deterioration in	
patients on treatment during, Duncan, M. E., <i>et al.</i> ....(A)	471
—, in dapsone-resistant leprosy. Duncan, M. E., <i>et al.</i> ....(A)	471
<b>Prothionamide,</b>	
and prothionamide-S-oxide in experimental leprosy. MATSUO, Y., <i>et al.</i> ....(O)	302
<b>Reaction(s),</b>	
conversion of, to lepromin and lepromin in patients with lepromatous leprosy by the	
transfer factor. Han, S. H., <i>et al.</i> ....(A)	370
histological course of, in borderline leprosy. RIDLEY, D. S. and RADIA, K. B. ....(O)	383
lepra, clofazimine (Lamprene; B663) in. Imkamp, F. M. J. H. ....(A)	470
—, a study of liver damage in leprosy patients during. Kim, D. L. ....(A)	366
liver lesions in reactional states in leprosy. Gharpuray, S. M., <i>et al.</i> ....(A)	472
Mitsuda, comparative study with integral human and armadillo lepromin in 50 patients	
with leprosy. Zambrano, T., <i>et al.</i> ....(A)	368
psychological, to leprosy. Behere, P. B. ....(A)	376
reversal, considerations on. Gatti, J. C., <i>et al.</i> ....(A)	471
—, management of. VAN DER MEULEN, J. and MOCK, B. ....(C)	457
reply to Dr. van der Meulen and Dr. Mock's Letter to the Editor. NAAFS, B. ....(C)	459
<b>Renal functions,</b>	
in lepromatous leprosy. BAJAJ, A. K., <i>et al.</i> ....(O)	37
—, Sritharan, V., <i>et al.</i> ....(A)	474
histological and biochemical assessment of severity of renal amyloidosis. Bhuyan,	
U. N. ....(A)	486
sequential, in leprosy. Bajaj, A. K., <i>et al.</i> ....(A)	363
study of percutaneous renal biopsy in lepromatous leprosy. Gupta, S. C. ....(A)	369
<b>Respiration,</b>	
breath holding time in leprosy. MALIK, S. K., <i>et al.</i> ....(C)	94
<b>Rheumatoid arthritis,</b>	
effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin	

and the erythrocyte sedimentation rate in rheumatoid arthritis. McConkey, B., <i>et al.</i> . . . . .(A)	270
<b>Rheumatoid factor,</b> manifestations in leprosy. Albert, D. A., <i>et al.</i> . . . . .(A)	127
<b>Rifampin,</b> asociada a levamisol. Wilkinson, F. and Liturri, M. . . . .(A)	127
controlled trial to compare the therapeutic effects of dapsone in combination with. OPROMOLLA, D. V. A., <i>et al.</i> . . . . .(O)	393
effect of single dose (1500 mg) on infectivity of patients with lepromatous leprosy. Girdhar, B. K., <i>et al.</i> . . . . .(A)	123
estudio bioquímico de pacientes con lepra lepromatosa tratados con rifampicina y 2-mercaptopropionilglicina. Wilkinson, F. F. and Gervasi, V. . . . .(A)	127
interaction with other drugs. Acocella, G. . . . .(A)	121
once monthly with daily Lamprene® and dapsone in treatment of refractory patients with lepromatous leprosy. PAUL, S. and ROSE, E. T. . . . .(C)	342
introductory, followed by dapsone therapy, persister <i>M. leprae</i> after. Sreevasta, B. K., <i>et al.</i> . . . . .(A)	470
<b>Rifamycins,</b> comparison of antibacterial and antiimmune effects of. Kasik, J. E. and Monik, M. . . .(A)	269
multivariate analysis of, against rapidly growing mycobacteria, to define an <i>in vitro</i> screening model for their activity against <i>M. leprae</i> . Pattyn, S. R. and Hebrant, F. (A)	373
<b>Serotonin,</b> blood levels of, in human leprosy. Kumar, B., <i>et al.</i> . . . . .(A)	129
antileprosy and biological antioxidant activity of. BERGEL, M. . . . .(C)	259
uptake, by platelets, low, in leprosy, prevention of. SZABADOS, L., <i>et al.</i> . . . . .(O)	42
<b>Serum lipids,</b> in leprosy. Kumar, B., <i>et al.</i> . . . . .(A)	129
<b>Sexual dysfunction,</b> in leprosy. ROLSTON, R., <i>et al.</i> . . . . .(O)	31
—, and female genital organs. Sharma, S. C., <i>et al.</i> . . . . .(A)	272
—, and female reproductive organs. Sharma, S. C., <i>et al.</i> . . . . .(A)	177
<b>Skin,</b> advances in dermatology. Ratnam, A. V. . . . .(A)	134
adnexa in leprosy and their role in the dissemination of <i>M. leprae</i> . Kotteswaran, G., <i>et al.</i> . . . . .(A)	132
bacterial and histopathological study of apparently normal skin in lepromatous leprosy. Katoch, V. M., <i>et al.</i> . . . . .(A)	131
detection of mycobacterial lipids in biopsies of. YOUNG, D. B. . . . .(O)	198
psoriasis and other common dermatoses in leprosy. Wahba, A., <i>et al.</i> . . . . .(A)	131
slit . . . smears, choice of sites for study of. Kaur, S., <i>et al.</i> . . . . .(A)	366
smears of leprosy patients, comparative study on various staining methods for <i>M.</i> <i>leprae</i> in. Kim, D. and Hak-Bung, K. . . . .(A)	370
significance of anesthetic macules in the early diagnosis of leprosy. Sun, Y. X. and Chou, H. . . . .(A)	367
<b>Skinsnes, Olaf K.</b> personal. . . . .(N)	106
<b>Social aspects,</b> <i>Health Education and Social Aspects in Leprosy Work.</i> Mehendale, M. S. . . . .(B)	266
image, education, and doctor-patient relationships. de Mesquita, A. P. . . . .(A)	485
psychodynamic side of leprosy. Chauhan, N. S. and Dhar, U. . . . .(A)	484
study of stigma among leprosy patients attending clinic in Gwalior. Kushwah, S. S., <i>et al.</i> . . . . .(A)	377
<b>Spain,</b> leprosy in Murcia Province, ambulatory and hospital aspects. Castro Díez, M. C., <i>et al.</i> . . . . .(A)	281
two leprosy courses held at Fontilles. . . . .(N)	107

<b>Spleen,</b>		
T cell depletion of, in patients with longstanding lepromatous leprosy. Mathias, C. ... (A)		133
<i>The Role of the Spleen in the Immunology of Parasitic Diseases.</i> ... (B)		118
<b>Sulfones,</b>		
haemagglutination inhibition technique for demonstration of, in urine. Huikeshoven, H., <i>et al.</i> ... (A)		469
in body fluids, ELISA inhibition technique, for demonstration of, comparison of two ELISA methods. deWit, M., <i>et al.</i> ... (A)		468
—, —, —, a new method to monitor leprosy patient compliance under field conditions. Huikeshoven, H., <i>et al.</i> ... (A)		361
—, —, —, use of dried blood on filter paper to monitor patient compliance. Huikeshoven, H., <i>et al.</i> ... (A)		469
-induced exfoliative dermatitis and hepatitis. Lal, S. and Garg, B. R. ... (A)		125
mechanism of action of. BERGEL, M. ... (C)		89
secondary resistance to, in leprosy. Lal, S., <i>et al.</i> ... (A)		125
therapy, influence of on lepromin reaction. Ramu, G., <i>et al.</i> ... (A)		126
<b>Switzerland,</b>		
Financial problems of tropical diseases discussed. ... (N)		263
Fourth annual report of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ... (N)		107
IMMLEP, Fifth Meeting of Scientific Working Group. ... (N)		353
IMMLEP, Sixth Meeting of Steering Committee of SWG. ... (N)		355
IMMLEP Subcommittee meeting on planning of leprosy vaccine trials. ... (N)		353
International Year of Disabled Persons (IYDP) (1981) plans made by Council of World Organizations Interested in the Handicapped (CWOIH). ... (N)		108
report of the third meeting of the Scientific Working Group on Chemotherapy of Leprosy (THELEP) of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ... (O)		431
Steering Committee of Scientific Working Group on Chemotherapy of Leprosy. ... (N)		354
Third meeting of Trans Disease Scientific Working Group on Epidemiology of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ... (N)		108
34th World Health Assembly, address by Mrs. Indira Gandhi, Prime Minister of India. ... (N)		355
WHO experts recommend continued use of BCG vaccination against tuberculosis. ... (N)		464
<b>Tanzania,</b>		
Scientific Conference on the Epidemiology of Leprosy held by Tanzanian Leprosy Association and Government of Tanzania. ... (N)		108
<b>Technology(ies),</b>		
appropriate for the future. Browne, S. G. ... (A)		359
<b>Testis,</b>		
leprosy. El-Beheiry, A., <i>et al.</i> ... (A)		271
<b>Thalidomide,</b>		
anti-inflammatory immunosuppressive . . . analogs. Piper, L. M., <i>et al.</i> ... (A)		511
immunosuppressive/anti-inflammatory . . . analogs. Hastings, R. C., <i>et al.</i> ... (A)		123
inhibition of de novo IgM antibody synthesis by, as a relevant mechanism of action in leprosy. Shannon, E. J., <i>et al.</i> ... (A)		478
structure activity relationship studies of . . . analogs as anti-inflammatory and immunosuppressive agents. Agrawal, K. C., <i>et al.</i> ... (A)		512
treatment with, in steroid dependency and neuritis. Theophilus, S. ... (A)		126
<b>THELEP,</b>		
approach to dapsone resistant leprosy. ... (O)		421
<b>Thiosemicarbazones,</b>		
2-acetylpyridine, antileprosy activity of. Morrison, N. E. ... (A)		510
<b><sup>3</sup>H Thymidine,</b>		
uptake of, in <i>M. leprae</i> inoculated mouse macrophage cultures as a rapid inhibitor of bacillary viability. SATHISH, M. and NATH, I. ... (O)		187

<b>Transfer factor,</b>		
conversion of reactions to lepromin and lepromin in patients with lepromatous leprosy by. Han, S. H., <i>et al.</i> . . . . .(A)		370
<b>Treatment,</b>		
adherence to drug therapy, an outpatient survey. Kritzinger, N. A. . . . .(A)		269
assessment of dapsone self-administration in Gudiyatham Taluk. Cates, C. J. . . . .(A)		360
dapsone compliance in North-east India. Davies, R. A. and Ng, Y. Y. . . . .(A)		361
<i>in vitro</i> study of the effects of home-made porcine thymosin on cellular immunity in leprosy patients—T cell responses. . . . .(A)		135
patient compliance with dapsone administration in leprosy. HUIKESHOVEN, H. . . . .(E)		228
of leprosy, a personal view. Pattyn, S. R. . . . .(A)		125
<b>Tropical diseases,</b>		
<i>The Membrane Pathobiology of Tropical Diseases.</i> Hastings, R. C. . . . .(B)		117
<b>Tuberculoid leprosy,</b>		
borderline, following BCG vaccination. STONER, G., <i>et al.</i> . . . . .(O)		16
evolution of nasal mucosal lesions in. Mehta, L., <i>et al.</i> . . . . .(A)		140
HLA-linked control of susceptibility to, and association of HLA-DR types. de Vries, R. R. P., <i>et al.</i> . . . . .(A)		140
<b>Tuberculosis,</b>		
antituberculosis activity of 6 cyclo-octylamino-5,8-quinolinequinone (CQQ). Chakra- borty, A. . . . .(A)		468
congenital, cutaneous eruptions in. McCray, M. K. and Easterly, N. B. . . . .(A)		487
cutaneous, cell mediated immunity in. Sengupta, L. K., <i>et al.</i> . . . . .(A)		488
determining the prevalence of, in populations with non-specific tuberculin sensitiv- ity. ten Dam, H. G. . . . .(A)		145
domiciliary, controlled study of the effect of chemotherapy program in South India. Frimodt-Moller, J., <i>et al.</i> . . . . .(A)		486
enzyme-linked immunosorbent assay using arabinomannan from <i>M. smegmatis</i> : results in patients with, and with leprosy, and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. . . . .(A)		506
human, antibodies to mycobacteria in. Kaplan, M. H. and Chase, M. W. . . . .(A)		275
immunogenetics of susceptibility to leprosy, . . . , and leishmaniasis, an epidemio- logical perspective. FINE, P. E. M. . . . .(E)		437
<i>Leprosy-Tuberculosis Eradication.</i> Freerksen, E. and Rosenfeld, M. . . . .(B)		114
present status and future prospects of chemotherapy of leprosy based on experience with treating . . . . ACOCELLA, G. . . . .(O)		331
pulmonary, a randomized study of two policies for managing default outpatients collecting supplies of drugs for, in a large city in South India. Krishnaswami, K. V., <i>et al.</i> . . . . .(A)		487
—, a third study of case-finding methods for, in Kenya. Nsanzumuhire, H., <i>et al.</i> . . . .(A)		483
—, clinical trial of six-month and four-month regimens of chemotherapy in the treatment of. Singapore Tuberc. Service/Brit. Med. Res. Council. . . . .(A)		489
—, serum electrophoretic pattern in amyloidosis. Patra, S. B., <i>et al.</i> . . . . .(A)		488
—, smear positive, immunological and clinical features of, in East Java. Kardjito, T. and Grange, J. M. . . . .(A)		283
soluble antigen fluorescent antibody (SAF) test in sero-diagnosis of. Bhardwaj, O. P., <i>et al.</i> . . . . .(A)		485
specificity of the humoral immune response to soluble mycobacterial antigens in. Grange, J. M., <i>et al.</i> . . . . .(A)		144
trial of BCG vaccines in South India for prevention of. . . . .(A)		145
XXV World Conference of the International Union Against Tuberculosis, Buenos Aires. . . . .(N)		97
WHO recommends continued use of BCG vaccination against. . . . .(N)		464
<b>Turkey,</b>		
leprosy work in. . . . .(N)		109
<b>Ulcer(s),</b>		
leprous neurotrophic, squamous-cell carcinoma arising in. Troy, J. L., <i>et al.</i> . . . . .(A)		272
plantar, arteriographic pattern of, in lepromatous leprosy. Debi, B. P., <i>et al.</i> . . . . .(A)		128

<b>United Kingdom,</b>		
clofazimine (Lamprene, B663) in treatment of lepromatous leprosy in, a 12 year re-view of 31 cases. BROWNE, S. G., <i>et al.</i> . . . . .(O)		167
history of LEPROA. . . . .(N)		110
Manson Medal awarded to Dr. R. J. W. Rees. . . . .(N)		110
St. George's-tide Reunion of the Order of St. Lazarus confers Silver Medal on Dr. Stanley G. Browne. . . . .(N)		357
<b>U.S.A.,</b>		
anniversary (75th) of American Leprosy Missions. . . . .(N)		356
Department of Health and Human Services Honor Awards. . . . .(N)		465
International Seminar on Leprosy & Workshop on Training. . . . .(N)		265
Leonard Wood Memorial announces new leadership. . . . .(N)		465
International Conference on Training and Support of Primary Health Care Workers held in Washington, D.C. . . . .(N)		356
Inter-American Foundation, fellowships in international health. . . . .(N)		356
Heiser Program for Research in Leprosy announces 1982 research opportunities. . . . .(N)		357
National Council for International Health (NCIH)—1981 International Health Conference. . . . .(N)		264
—, course entitled "New Developments in Tropical Medicine". . . . .(N)		264
rising incidence of leprosy in. Levis, W. R. and Hedrick, J. L. . . . .(A)		376
third 5-year report (1975–1980) of U.S.-Japan Cooperative Medical Science Program. (N)		110
<b>U.S.-Japan Cooperative Medical Science Program,</b>		
five-year report issued. . . . .(N)		110
Sixteenth Joint Leprosy Conference, Bethesda, Maryland, 13–14 July 1981. . . . .(—)		490
<b>USSR,</b>		
International Conference on Primary Health Care. . . . .(N)		466
<b>Vaccine(s),</b>		
antileprosy, searches among mycobacterial cultures for. . . . .(A)		139
malaria, a perspective on. Desowitz, R. S. and Miller, L. H. . . . .(A)		283
<b>Vascular changes,</b>		
in leprosy, role in the pathogenesis of leprous neuritis. Chopra, J. S., <i>et al.</i> . . . . .(A)		471
—, their responsibility in skin and nerve changes and visceral lesions. Carayon, A., <i>et al.</i> . . . . .(A)		274
<b>Vietnam,</b>		
message from, on 50th anniversary of ILA. . . . .(N)		112
<b>Vitamins,</b>		
effect of, on serial cultivation of <i>M. lepraemurium</i> in axenic liquid medium and its implication in the culture of <i>M. leprae</i> . Nakamura, M. . . . .(A)		502
<b>Watelet, Robert,</b>		
1980 Damien-Dutton Award. . . . .(N)		260
<b>Yu Chia-Chun,</b>		
obituary. Skinsnes, O.; Hu, C. K. and Ye-Gan-yan. . . . .(Ob)		84